Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
CARDIZEM LA is a long-acting oral formulation of diltiazem hydrochloride, a non-dihydropyridine calcium channel blocker used to treat hypertension and angina pectoris. It works by inhibiting calcium influx into vascular smooth muscle and cardiac tissue, reducing heart rate and blood pressure. The extended-release tablet formulation enables once-daily dosing for improved patient compliance.
Product approaching loss of exclusivity with modest Part D spending; expect defensive marketing strategies and potential team consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Positions on CARDIZEM LA offer experience in mature-product management, competitive positioning, and payer negotiations in a declining market. Career value is highest for professionals developing skills in lifecycle management, cost-effectiveness strategies, and defensive commercial tactics before generic erosion accelerates.
Worked on CARDIZEM LA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo